Remibrutinib

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.

20+ companies, including Regeneron and Sanofi, are advancing 25+ urticaria drugs through clinical trials, addressing unmet needs in treatment.

Hidradenitis suppurativa (HS) treatment insights highlight B cells, fibroblasts, and bacterial triggers as central to inflammation and fibrosis, with recent trials showing varying success rates for therapies targeting these elements, necessitating further research to understand HS pathogenesis and optimize treatment responses.

Fall Clinical 2024 in Las Vegas featured experts discussing emerging therapies, patient care strategies, and research findings. Highlights included advancements in melanoma prognosis, atopic dermatitis treatments shifting from corticosteroids to JAK inhibitors, new lasers for acne and rosacea, innovations in aesthetic dermatology, monoclonal antibodies and JAK inhibitors for skin conditions, treatments for alopecia areata and refractory dermatoses, insights on palmoplantar pustulosis and psoriasis comorbidities, understanding itch pathways, chronic hand eczema, and the importance of itch severity assessment in dermatology.

Sanofi and Regeneron plan to resubmit an FDA application for Dupixent in chronic spontaneous urticaria (CSU) by year-end, after a trial showed a 50% reduction in itch and urticaria activity scores. The companies also announced positive results in bullous pemphigoid and plan to seek U.S. approval for this indication. Despite challenges, Dupixent is used by 1 million patients across seven indications, with Japan being the first to approve it for CSU.

Novartis' Phase III V-MONO trial of Leqvio met primary endpoints, showing significant LDL-C reduction in low/moderate ASCVD risk patients. The trial compared Leqvio monotherapy against ezetimibe and placebo, with findings to be discussed with regulatory authorities.